330 related articles for article (PubMed ID: 31595663)
1. Phase II study of temozolomide and topotecan (TOTEM) in children with relapsed or refractory extracranial and central nervous system tumors including medulloblastoma with post hoc Bayesian analysis: A European ITCC study.
Le Teuff G; Castaneda-Heredia A; Dufour C; Jaspan T; Calmon R; Devos A; McHugh K; Leblond P; Frappaz D; Aerts I; Zwaan CM; Ducassou S; Chastagner P; Verschuur A; Corradini N; Casanova M; Rubie H; Riccardi R; Le Deley MC; Vassal G; Geoerger B;
Pediatr Blood Cancer; 2020 Jan; 67(1):e28032. PubMed ID: 31595663
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study.
Di Giannatale A; Dias-Gastellier N; Devos A; Mc Hugh K; Boubaker A; Courbon F; Verschuur A; Ducassoul S; Malekzadeh K; Casanova M; Amoroso L; Chastagner P; Zwaan CM; Munzer C; Aerts I; Landman-Parker J; Riccardi R; Le Deley MC; Geoerger B; Rubie H
Eur J Cancer; 2014 Jan; 50(1):170-7. PubMed ID: 24021349
[TBL] [Abstract][Full Text] [Related]
3. Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial.
Cefalo G; Massimino M; Ruggiero A; Barone G; Ridola V; Spreafico F; Potepan P; Abate ME; Mascarin M; Garrè ML; Perilongo G; Madon E; Colosimo C; Riccardi R
Neuro Oncol; 2014 May; 16(5):748-53. PubMed ID: 24482446
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Nicholson HS; Kretschmar CS; Krailo M; Bernstein M; Kadota R; Fort D; Friedman H; Harris MB; Tedeschi-Blok N; Mazewski C; Sato J; Reaman GH
Cancer; 2007 Oct; 110(7):1542-50. PubMed ID: 17705175
[TBL] [Abstract][Full Text] [Related]
5. Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study.
Hawkins DS; Bradfield S; Whitlock JA; Krailo M; Franklin J; Blaney SM; Adamson PC; Reaman G
Pediatr Blood Cancer; 2006 Nov; 47(6):790-4. PubMed ID: 16435380
[TBL] [Abstract][Full Text] [Related]
6. Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials.
Moreno L; Rubie H; Varo A; Le Deley MC; Amoroso L; Chevance A; Garaventa A; Gambart M; Bautista F; Valteau-Couanet D; Geoerger B; Vassal G; Paoletti X; Pearson AD
Pediatr Blood Cancer; 2017 Jan; 64(1):25-31. PubMed ID: 27555472
[TBL] [Abstract][Full Text] [Related]
7. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor.
Stewart CF; Iacono LC; Chintagumpala M; Kellie SJ; Ashley D; Zamboni WC; Kirstein MN; Fouladi M; Seele LG; Wallace D; Houghton PJ; Gajjar A
J Clin Oncol; 2004 Aug; 22(16):3357-65. PubMed ID: 15310781
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of preradiotherapy chemotherapy followed by hyperfractionated radiotherapy for newly diagnosed high-risk medulloblastoma/primitive neuroectodermal tumor: a report from the Children's Oncology Group (CCG 9931).
Allen J; Donahue B; Mehta M; Miller DC; Rorke LB; Jakacki R; Robertson P; Sposto R; Holmes E; Vezina G; Muraszko K; Puccetti D; Prados M; Chan KW
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1006-11. PubMed ID: 19356859
[TBL] [Abstract][Full Text] [Related]
9. Irinotecan, vincristine, cisplatin, cyclophosphamide, and etoposide for refractory or relapsed medulloblastoma/PNET in pediatric patients.
Kim H; Kang HJ; Lee JW; Park JD; Park KD; Shin HY; Ahn HS
Childs Nerv Syst; 2013 Oct; 29(10):1851-8. PubMed ID: 23748464
[TBL] [Abstract][Full Text] [Related]
10. Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411).
Schafer ES; Rau RE; Berg SL; Liu X; Minard CG; Bishop AJR; Romero JC; Hicks MJ; Nelson MD; Voss S; Reid JM; Fox E; Weigel BJ; Blaney SM
Pediatr Blood Cancer; 2020 Feb; 67(2):e28073. PubMed ID: 31724813
[TBL] [Abstract][Full Text] [Related]
11. Outcome for children treated for medulloblastoma and supratentorial primitive neuroectodermal tumor (CNS-PNET) - a retrospective analysis spanning 40 years of treatment.
Stensvold E; Krossnes BK; Lundar T; Due-Tønnessen BJ; Frič R; Due-Tønnessen P; Bechensteen AG; Myklebust TÅ; Johannesen TB; Brandal P
Acta Oncol; 2017 May; 56(5):698-705. PubMed ID: 28325133
[TBL] [Abstract][Full Text] [Related]
12. Progressive disease in children with medulloblastoma/PNET during preradiation chemotherapy.
Tornesello A; Mastrangelo S; Piciacchia D; Bembo V; Colosimo C; Di Rocco C; Mastrangelo R
J Neurooncol; 1999; 45(2):135-40. PubMed ID: 10778729
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours.
Rubie H; Geoerger B; Frappaz D; Schmitt A; Leblond P; Ndiaye A; Aerts I; Le Deley MC; Gentet JC; Paci A; Chastagner P; Dias N; Djafari L; Pasquet M; Chatelut E; Landman-Parker J; Corradini N; Vassal G
Eur J Cancer; 2010 Oct; 46(15):2763-70. PubMed ID: 20558056
[TBL] [Abstract][Full Text] [Related]
14. Hypofractionated stereotactic radiotherapy in the management of recurrent or residual medulloblastoma/PNET.
Saran F; Baumert BG; Creak AL; Warrington AP; Ashley S; Traish D; Brada M
Pediatr Blood Cancer; 2008 Mar; 50(3):554-60. PubMed ID: 17941071
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer.
Heist RS; Fain J; Chinnasami B; Khan W; Molina JR; Sequist LV; Temel JS; Fidias P; Brainerd V; Leopold L; Lynch TJ
J Thorac Oncol; 2010 Oct; 5(10):1637-43. PubMed ID: 20808253
[TBL] [Abstract][Full Text] [Related]
16. Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study.
Strother D; Ashley D; Kellie SJ; Patel A; Jones-Wallace D; Thompson S; Heideman R; Benaim E; Krance R; Bowman L; Gajjar A
J Clin Oncol; 2001 May; 19(10):2696-704. PubMed ID: 11352962
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study.
Grill J; Geoerger B; Gesner L; Perek D; Leblond P; Cañete A; Aerts I; Madero L; de Toledo Codina JS; Verlooy J; Estlin E; Cisar L; Breazna A; Dorman A; Bailey S; Nicolin G; Grundy RG; Hargrave D;
Neuro Oncol; 2013 Sep; 15(9):1236-43. PubMed ID: 23857707
[TBL] [Abstract][Full Text] [Related]
18. Results of treatment of children with recurrent medulloblastoma/primitive neuroectodermal tumors with lomustine, cisplatin, and vincristine.
Lefkowitz IB; Packer RJ; Siegel KR; Sutton LN; Schut L; Evans AE
Cancer; 1990 Feb; 65(3):412-7. PubMed ID: 2153428
[TBL] [Abstract][Full Text] [Related]
19. Activity of postoperative carboplatin, etoposide, and high-dose methotrexate in pediatric CNS embryonal tumors: results of a phase II study in newly diagnosed children.
Kellie SJ; Wong CK; Pozza LD; Waters KD; Lockwood L; Mauger DC; White L
Med Pediatr Oncol; 2002 Sep; 39(3):168-74. PubMed ID: 12210445
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab-containing regimen in relapsed/progressed brain tumors: a single-institution experience.
Schiavetti A; Varrasso G; Mollace MG; Dominici C; Ferrara E; Papoff P; Di Biasi C
Childs Nerv Syst; 2019 Jun; 35(6):1007-1012. PubMed ID: 30903281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]